Biofrontera Inc. (BFRI) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Biofrontera's earnings call highlights strong revenue growth, record high quarterly revenue, and significant improvements in gross profit margins and net income. The company's strategic initiatives, including product expansion and cost management, are on track, with optimistic guidance for 2026. Despite risks like legal costs and competition, the overall sentiment is positive, supported by improved financial metrics and promising product developments. The lack of concerning responses in the Q&A further solidifies the positive outlook for the stock price over the next two weeks.
Key Financial Performance
Annual Revenue for 2025 $41.7 million, representing about 12% growth over the prior year. This growth was driven by strong commercial execution and increased adoption of Ameluz PDT.
Fourth Quarter Revenue for 2025 $17.1 million, the highest quarterly revenue in the company's history, representing approximately 36% year-over-year growth. This was driven by strong Ameluz sales execution and pricing adjustments introduced in December 2025.
Adjusted EBITDA for Q4 2025 $4.9 million, a significant improvement from negative $1.4 million in Q4 2024. This improvement was due to higher revenues, lower cost of goods sold, and improved operating cost management.
Net Income for Q4 2025 $5.6 million, a $7 million improvement from a net loss of $1.4 million in Q4 2024. This was driven by higher revenues and lower costs of revenues.
Gross Profit Margin for Q4 2025 82%, up from 58% in Q4 2024. This improvement was due to a transition to a lower earn-out structure from a previous transfer pricing model.
Annual Gross Profit Margin for 2025 74%, up from 50% in 2024. This was driven by the transition to a lower earn-out structure and improved cost management.
Operating Loss for 2025 $11.3 million, a significant improvement from a net loss of $17.2 million in 2024. This was due to higher revenues and lower costs from the strategic transaction.
Net Loss for 2025 $10.5 million, a significant improvement from a net loss of $17.8 million in 2024. This was driven by higher revenues and lower costs of revenues.
Adjusted EBITDA for 2025 Negative $10.6 million, an improvement from negative $15.3 million in 2024. This was due to higher gross profit and improved operational cost management.
Cash and Cash Equivalents as of December 31, 2025 $6.4 million, up from $5.9 million at the end of 2024. This increase was due to proceeds from private placements and the Xepi divestiture.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Ameluz PDT adoption: Record annual revenues of $41.7 million, a 12% growth over the prior year, driven by growing adoption of Ameluz PDT in the dermatology community.
New drug applications: Submitted a supplemental new drug application for superficial basal cell carcinoma (sBCC) with a PDUFA target action date of September 28, 2026. Positive Phase III results for actinic keratosis (AK) on extremities, neck, and trunk, with plans to file a supplemental NDA in Q3 2026. Positive Phase II results for moderate to severe acne vulgaris, with plans for a Phase III program discussion in Q3 2026.
Patent portfolio: Strengthened with approval for a new Ameluz formulation extending patent protection through December 2043. Positive outcome in a patent dispute with Sun Pharma.
Market expansion for Ameluz: Expanded label opportunities for Ameluz to treat sBCC, AK on extremities, neck, and trunk, and potential for moderate to severe acne vulgaris. These expansions target large addressable markets.
RhodoLED lamp placements: Placed 85 BF-RhodoLED lamps in 2025, increasing the installed base to 745 lamps across 686 dermatology offices.
Cost structure improvement: Transitioned from a transfer pricing model to a lower earn-out structure, reducing cost of revenues per unit to 15% from 25%-35%, improving gross profit margins to 82% in Q4 2025.
Revenue growth: Achieved record quarterly revenue of $17.1 million in Q4 2025, a 36% year-over-year growth.
Operational efficiencies: Revamped commercial strategy with refined customer segmentation, data-driven targeting, and increased in-person sales activity. Launched an inside sales pilot to cover smaller accounts.
Strategic transaction with Biofrontera AG: Acquired all U.S. rights, approvals, and patents for Ameluz and RhodoLED, including manufacturing rights and intellectual property, improving financial flexibility and operational control.
Funding and divestment: Secured $11 million in funding through private placement and completed the sale of Xepi antibiotic cream license for $3 million upfront, with potential for $7 million in milestone payments.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Legal Costs: Legal costs increased significantly, driven by patent claims and disputes, including ongoing litigation with Sun Pharma. This represents a financial burden and potential distraction for the company.
Supply Chain and Cost Structure: While the transition to a new earn-out structure has improved gross margins, the company is still adjusting to the new supply chain and cost structure, which could pose operational challenges.
Regulatory Risks: The company is awaiting FDA approval for supplemental NDAs and Phase III programs. Delays or rejections could impact strategic plans and revenue growth.
Market Competition: The company faces competitive pressures, particularly in the dermatology and acne treatment markets, which could impact market share and pricing.
Financial Liquidity: Although cash reserves have improved, the company remains reliant on institutional investors and milestone payments, which could pose risks if funding sources are disrupted.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Ameluz PDT for superficial basal cell carcinoma (sBCC): The FDA has accepted the supplemental new drug application for Ameluz PDT based on strong Phase III data. A PDUFA target action date is set for September 28, 2026. If approved, Ameluz would be the first PDT drug approved to treat a tumor in the U.S., representing a new commercial opportunity.
Ameluz PDT for actinic keratosis (AK) on extremities, neck, and trunk: Positive Phase III results were announced in February 2026. A supplemental NDA is anticipated to be filed in Q3 2026 to expand the label for Ameluz to treat AK beyond the face and scalp. This expansion targets a large addressable market of approximately 58 million American adults with at least one AK lesion.
Ameluz PDT for moderate to severe acne vulgaris: Positive Phase II results were announced, showing a 58% reduction in inflammatory lesions. Plans to discuss a Phase III program design with the FDA are set for Q3 2026. This represents a potential differentiated treatment option for a chronic condition affecting millions.
Gross profit margin improvement: The company expects gross profit margins to range between 80% and 85% in 2026, driven by a new cost structure under the earn-out agreement.
Inside sales rollout: Following a successful pilot in Q4 2025, a full rollout of inside sales is planned for 2026 to cover vacant territories and smaller accounts.
Operational improvements and cash flow: Operational improvements, including greater control over the supply chain and shorter lead times, are expected to reduce cash consumption and advance towards cash flow breakeven.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the anticipated gross profit margins for 2026 and how will they evolve over the year?
A:The gross profit margins are expected to be between 80% and 85%, depending on the mix between Ameluz and device sales. This range is expected to remain consistent from January 1, 2026, throughout the year.
Q:Will the gross profit margins start at a specific level and remain stable, or will they vary over the year?
A:The margins are expected to start at around 82% and may fluctuate slightly depending on the product mix in revenue and cost of goods sold.
Q:Review of Unclear Management Responses
A:No questions were avoided or lacked clarity in the responses provided by management.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Full Financial
Inc
NDA
PDT
Phase III
RhodoLED lamp
Sun Pharma
account
adoption
change
clearance
decision
dermatology
design
drug application
field
form
history
milestone
parent AG
person
phase database
pilot
placebo
potential
progress
record revenue
sBCC
section
stock
transaction
treatment phase
unit volume
volume tube
volume unit
BFRI Transcript
Biofrontera Inc. (BFRI) Q4 2025 Earnings Call Transcript
Positive3-19
Biofrontera's earnings call highlights strong revenue growth, record high quarterly revenue, and significant improvements in gross profit margins and net income. The company's strategic initiatives, including product expansion and cost management, are on track, with optimistic guidance for 2026. Despite risks like legal costs and competition, the overall sentiment is positive, supported by improved financial metrics and promising product developments. The lack of concerning responses in the Q&A further solidifies the positive outlook for the stock price over the next two weeks.
Biofrontera Inc. (BFRI) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call highlights increased net loss, decreased revenue, and high legal expenses, which are negative indicators. The Q&A suggests potential for future growth with planned price increases and FDA submissions, but these are not immediate catalysts. Limited cash reserves pose liquidity risks, and ongoing legal costs are concerning. Overall, the financial health and immediate outlook are weak, leading to a negative sentiment.
Biofrontera Inc. (BFRI) Q2 2025 Earnings Conference Call Transcript
Positive8-14
The earnings call highlights a strong financial performance with a 15.4% revenue increase and reduced cost of revenues. Despite a net loss, the significant reduction in costs and improved adjusted EBITDA are promising. The Q&A section reveals positive sentiment towards gross margin improvements and upcoming FDA submissions. Although legal costs increased, they are not expected to persist. The lack of a price hike and expected cash inflow further support a positive outlook. Overall, the financial and strategic updates suggest a positive stock price movement in the next two weeks.
Biofrontera Inc. (NASDAQ:BFRI) Q1 2025 Earnings Call Transcript
Unknown5-20
The earnings call reveals mixed signals: strong sales growth and FDA approvals are positive, but challenges like increased R&D expenses, legal costs, and regulatory risks pose concerns. The Q&A section shows management's lack of clarity on certain sales data, which can worry investors. Despite a record revenue expectation for 2025, the lack of a share repurchase program and reduced cash position offset positives. Given these factors, and without market cap data, a neutral stock price movement is anticipated over the next two weeks.
BFRI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
